Development of quantitative biomarker strategies for proteopathies through seragy’s proprietary Se

通过Seragy专有的Se技术开发针对蛋白质病变的定量生物标志物策略

RAS

RAS

®

®

technology

技术

Expansion of the company’s laboratory and analytical capabilities with funding from Commerzbank, the Mittelständische Beteiligungsgesellschaft (MBG), and the State of Lower Saxony

在商业银行、中型企业参与公司（MBG）和下萨克森州政府的资助下，扩大公司的实验室和分析能力

Separate funding from The Michael J. Fox Foundation provides support for a quantitative Se

来自迈克尔·J·福克斯基金会的独立资金为定量研究提供支持

RAS

RAS

-based assay for Parkinson’s disease

基于...的帕金森病检测方法

Hanover, Germany, Oct. 14, 2026 (GLOBE NEWSWIRE) --

德国汉诺威，2026年10月14日（环球电讯社）--

seragy holding GmbH

seragy 控股有限公司

(formerly Prosperodes GmbH), a biomarker strategy company focused on neurodegenerative diseases and other proteopathies, has secured €12 million in funding to accelerate the development of its Se

（前身为 Prosperodes GmbH）是一家专注于神经退行性疾病及其他蛋白质病变的生物标志物策略公司，已获得 1200 万欧元融资，以加速其 Se

RAS

RAS

®

注册商标

platform (

平台（

Se

硒

ed

ed

R

R

eplication,

复制

A

A

nalysis and

分析和

S

S

ubtyping) and expand its laboratory and analytical capabilities. The financing is backed by

亚型）并扩大其实验室和分析能力。该融资由

Commerzbank

德国商业银行

, the

，这

Mittelständische Beteiligungsgesellschaft (MBG)

中型企业参股公司（MBG）

, and the

，以及

State of Lower Saxony

下萨克森州

.

。

Proteopathies – such as Alzheimer’s, Parkinson’s, and ALS – are among the greatest challenges in modern medicine. These diseases are characterized by pathological protein aggregation and display substantial molecular heterogeneity, often with multiple distinct disease subtypes within one indication.

蛋白病——如阿尔茨海默病、帕金森病和肌萎缩侧索硬化症（ALS）——是现代医学面临的最大挑战之一。这些疾病的特征是病理性蛋白质聚集，并表现出显著的分子异质性，通常在单一适应症中存在多种不同的疾病亚型。

Current technologies often lack the ability to distinguish clinically relevant molecular patterns and quantify aggregation processes with the precision required for translational drug development..

现有技术往往缺乏区分具有临床意义的分子模式并以转化药物开发所需的精度量化聚集过程的能力。

Using its proprietary Se

使用其专有的 Se

RAS

RAS

technology, seragy develops quantitative, mechanism-relevant biomarkers that generate molecular fingerprints of pathological protein aggregation from patient samples. Unlike conventional seed amplification assays, which primarily provide binary detection without molecular resolution, these fingerprints will reveal quantitative biological changes and identify relevant subtypes of proteopathies.

在技术方面，Seragy 开发定量且与机制相关的生物标志物，能够从患者样本中生成病理性蛋白质聚集的分子指纹。与主要提供缺乏分子分辨率的二元检测的传统种子扩增 assays 不同，这些分子指纹将揭示定量的生物学变化，并识别蛋白质病变的相关亚型。

By translating aggregation biology into actionable biomarker insights, seragy will support pharmaceutical and biotechnology partners in developing more targeted therapeutic strategies from early discovery through clinical development..

通过将聚集生物学转化为可操作的生物标志物洞察，seragy 将支持制药和生物技术合作伙伴从早期发现到临床开发阶段制定更精准的治疗策略。

“This financing provides the foundation for us to transform how pathological protein aggregation is measured and understood,” said

“这笔融资为我们变革病理性蛋白质聚集的测量与认知方式奠定了基础，”

Dr. Thorsten Lührs, Managing Partner for Strategy & Innovation and Co-Founder of seragy.

Thorsten Lührs 博士，seragy 的战略与创新管理合伙人兼联合创始人。

“Together with our highly qualified interdisciplinary team, we will continue advancing Se

“与我们高素质的跨学科团队一起，我们将继续推进 Se

RAS

RAS

as a next-generation biomarker platform that makes aggregation processes measurable and biologically interpretable. Through our global collaborations with pharmaceutical and biotechnology partners, Se

作为一个下一代生物标志物平台，使聚集过程可测量且具有生物学可解释性。通过我们与全球制药和生物技术合作伙伴的协作，Se

RAS

RAS

provides insights informing therapeutic strategies and helps accelerate the development of effective treatments for patients with proteopathies. We thank Commerzbank, the MBG, and the State of Lower Saxony for their trust and commitment to our technology.”

提供有助于制定治疗策略的见解，并加速为蛋白质病患者开发有效疗法。我们感谢商业银行、MBG以及下萨克森州对我们技术的信任与支持。”

With this combination of debt financing, equity capital, and public funding, seragy will accelerate the further development and application of its Se

通过这种债务融资、股权资本和公共资金的组合，seragy 将加速其 Se 的进一步开发和应用

RAS

RAS

technology by expanding its laboratory and analytical capabilities and growing its team in Hanover. At the same time, the company will strengthen its presence in European and international markets and further expand its collaborations with pharmaceutical and biotechnology companies to provide translational biomarker strategies across early-stage discovery, preclinical, and clinical development..

通过扩大其在汉诺威的实验室和分析能力并壮大其团队，该公司将加强其在欧洲和国际市场的影响力，并进一步深化与制药和生物技术公司的合作，以提供涵盖早期发现、临床前及临床开发阶段的转化生物标志物策略。

“seragy combines scientific excellence and a clear vision with a highly innovative technology platform for addressing a critical challenge in developing treatments for neurodegenerative diseases,” said

“seragy 将卓越的科学实力、清晰的愿景与高度创新的技术平台相结合，以应对神经退行性疾病治疗开发中的关键挑战，”

Marc Hülsbruch, Chairman of the Management Board for Small-Business Customers in Lower Saxony at Commerzbank AG

马克·许尔斯布鲁赫，德国商业银行股份公司下萨克森州小企业客户管理委员会主席

. “By advancing cutting-edge technologies that ultimately help patients, companies like seragy demonstrate how a strong innovation ecosystem in Lower Saxony can contribute to the future of healthcare worldwide.”

“通过推进最终惠及患者的前沿技术，seragy 等公司展示了下萨克森州强大的创新生态系统如何为全球医疗健康的未来作出贡献。”

Separately, seragy is one of five recipients of funding from The

另外，seragy 是获得该资助的五家机构之一

Michael J. Fox Foundation for Parkinson’s Research (MJFF)

迈克尔·J·福克斯帕金森研究基金会（MJFF）

through its Seed Amplification Assay Innovation Program. The grant supports the development and evaluation of a quantitative biomarker assay for Parkinson’s disease and underscores the potential of the Se

通过其种子扩增检测创新计划。该资助支持帕金森病定量生物标志物检测的开发与评估，并突显了Se的潜力

RAS

RAS

technology to advance the development of translational biomarkers in neurodegenerative diseases.

用于推进神经退行性疾病转化生物标志物开发的技术。

About seragy holding GmbH

关于 seragy holding GmbH

seragy holding GmbH (formerly Prosperodes GmbH) is a biomarker strategy company based in Hanover, Germany. Through its wholly owned subsidiary seragy analytics GmbH and using its proprietary Se

seragy holding GmbH（前身为 Prosperodes GmbH）是一家总部位于德国汉诺威的生物标志物战略公司。通过其全资子公司 seragy analytics GmbH 并利用其专有的 Se

RAS

RAS

®

®

platform, the Company develops quantitative translational biomarkers for proteopathies - diseases driven by protein aggregation – including Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS). Seragy’s strategy is to generate molecular fingerprints of protein aggregates, which will reveal disease-specific subtypes and enable quantification of biological changes.

依托该平台，公司针对蛋白病（即由蛋白质聚集驱动的疾病，包括阿尔茨海默病、帕金森病和肌萎缩侧索硬化症[ALS]）开发定量转化生物标志物。Seragy的策略是生成蛋白质聚集体分子指纹，以揭示疾病特异性亚型并实现生物学变化的量化。

The goal is to accelerate the development of targeted therapies through deep insights into disease mechanisms and to improve the chances of success for new drugs through precise biomarkers..

目标是通过深入洞察疾病机制，加速靶向疗法的开发，并通过精准生物标志物提高新药研发的成功率。

Founded in 2022 as Prosperodes GmbH, seragy holding GmbH is led by Dr. Christiane Ritter and Dr. Thorsten Lührs, two scientists with nearly three decades of expertise in protein aggregation research, alongside Arne Ungruh, an experienced business and finance leader. The holding company owns the intellectual property, acts as the licensor and consolidates central holding functions, while operational activities, particularly services and projects for partner companies, are carried out by seragy analytics GmbH.

seragy holding GmbH 于 2022 年以 Prosperodes GmbH 之名成立，由克里斯蒂亚内·里特博士（Dr. Christiane Ritter）和托尔斯滕·吕尔斯博士（Dr. Thorsten Lührs）两位在蛋白质聚集研究领域拥有近三十年专业经验的科学家，以及经验丰富的商业与金融领导者阿内·温格鲁赫（Arne Ungruh）共同领导。该控股公司拥有知识产权，担任许可方，并整合中央控股职能，而运营活动，特别是为合作伙伴公司提供的服务和项目，则由 seragy analytics GmbH 负责执行。

The company is supported by The Michael J. Fox Foundation, Commerzbank AG, Mittelständische Beteiligungsgesellschaft Niedersachsen (MBG), and the State of Lower Saxony, among others..

该公司获得迈克尔·J·福克斯基金会、德国商业银行股份公司、下萨克森州中型企业参与公司（MBG）以及下萨克森州政府等机构的支持。

For more information, visit:

更多信息，请访问：

https://seragy.com/

https://seragy.com/

About Se

关于硒

RAS

RAS

®

®

Se

硒

RAS

RAS

®

®

(Seed Replication, Analysis, and Subtyping) is seragy’s proprietary technology platform for the highly sensitive analysis of pathological protein aggregates. As a further development of classical seed amplification assays, Se

（种子复制、分析与亚型分型）是 seragy 公司专有的技术平台，用于对病理性蛋白质聚集体进行高灵敏度分析。作为经典种子扩增 assays 的进一步发展，Se

RAS

RAS

combines seeding-based biochemistry with high-sensitivity optics, automated data analysis, software algorithms, and micromechanical components. At the heart of the platform is the

将基于种子的生物化学技术与高灵敏度光学系统、自动化数据分析、软件算法以及微机械组件相结合。该平台的核心是

Metis

墨提斯

One

一

®

®

Analyzer

分析器

, which has been designed to enable quantitative and reproducible measurements of protein aggregates from patient samples. Unlike conventional seed amplification assays, which primarily provide qualitative detection, Se

，其设计旨在实现对患者样本中蛋白质聚集体的定量且可重复的测量。与主要提供定性检测的传统种子扩增 assay 不同，Se

RAS

RAS

has been developed to generate quantitative molecular fingerprints that can be used to characterize aggregation patterns, distinguish molecular subtypes, and track biological changes over the course of a disease. The platform is designed for the development of translational biomarkers, from early drug discovery through preclinical and clinical development..

已开发出一种方法，用于生成定量分子指纹，这些指纹可用于表征聚集模式、区分分子亚型，并追踪疾病进程中的生物学变化。该平台旨在开发转化生物标志物，涵盖从早期药物发现到临床前和临床开发的全过程。

seragy Contact:

seragy 联系方式：

seragy holding GmbH

seragy 控股有限公司

info@seragy.com

info@seragy.com

Media Contact

媒体联系人

:

：

MC Services AG

MC 服务股份公司

Dr. Cora Kaiser / Dr. Regina Lutz

科拉·凯泽博士 / 雷吉娜·卢茨博士

Tel.: +49 (0)89 210 228 0

电话：+49 (0)89 210 228 0

E-Mail:

电子邮件：

seragy@mc-services.eu

seragy@mc-services.eu